A carregar...
A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
Activating double mutations L858R/T790M in the epidermal growth factor receptor (EGFR) region are often observed as the cause of resistance to tyrosine kinase inhibitors (TKIs). Third-generation EGFR-TKIs, such as osimertinib and rociletinib (CO-1686), was developed to target such resistance mutatio...
Na minha lista:
| Publicado no: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7998589/ https://ncbi.nlm.nih.gov/pubmed/33809064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14030256 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|